| Trial | Sponsor | Phase | Status | Primary completion |
|---|
| A Trial Evaluating Brelovitug (BJT-778) vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2)NCT07200908 | MIRM | Phase 3 | Recruiting | 2027-06-30Estimated |
| Open-Label Extension Study of WVE-N531 in Patients With Duchenne Muscular DystrophyNCT07209332 | Wave Life Sciences USA, Inc. | Phase 2 | Enrolling by invitation | 2029-03Estimated |
| Study of MRM-3379 in Male Participants With Fragile X Syndrome (BLOOM)NCT07209462 | MIRM | Phase 2 | Recruiting | 2027-10Estimated |
| A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated CardiomyopathyNCT07210723 | KARD | Phase 2, Phase 3 | Recruiting | 2027-09Estimated |
| A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Participants With Relapsing Multiple Sclerosis (RMS)NCT07211633 | TGTX | Phase 3 | Active not recruiting | 2026-10-31Estimated |
| A Study to Assess the Efficacy and Safety of ZL-1109 in Chinese Participants With Active Thyroid Eye DiseaseNCT07211776 | Zai Lab (Shanghai) Co., Ltd. | Phase 3 | Active not recruiting | 2027-03-14Estimated |
| Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 MutationNCT07211958 | Syndax Pharmaceuticals | Phase 3 | Recruiting | 2029-06Estimated |
| A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic DermatitisNCT07217015 | KYMR | Phase 2 | Active not recruiting | 2027-06Estimated |
| An Open-label Study of Azetukalner in Bipolar I or II Depression (X-CEED-OLE)NCT07217860 | XENE | Phase 3 | Active not recruiting | 2029-06Estimated |
| A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)NCT07218146 | Zai Lab (Shanghai) Co., Ltd. | Phase 3 | Recruiting | 2028-06-30Estimated |
| Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhine)NCT07218783 | SGP | Phase 3 | Recruiting | 2029-03-31Estimated |
| Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhone)NCT07218796 | SGP | Phase 3 | Recruiting | 2029-05-31Estimated |
| A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset SeizuresNCT07219407 | RAPP | Phase 2 | Recruiting | 2028-02-03Estimated |
| Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple SclerosisNCT07220252 | TGTX | Phase 2, Phase 3 | Recruiting | 2030-01-01Estimated |
| An Open-Label Extension Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1 (FREEDOM-OLE)NCT07220603 | PEPG | Phase 2 | Recruiting | 2029-01Estimated |
| A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)NCT07221500 | NRIX | Phase 2 | Recruiting | 2028-01Estimated |
| Study to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment of Social Anxiety DisorderNCT07221578 | Vanda Pharmaceuticals | Phase 3 | Active not recruiting | 2026-12Estimated |
| A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Psoriatic ArthritisNCT07223138 | MoonLake Immunotherapeutics AG | Phase 3 | Enrolling by invitation | 2028-02-04Estimated |
| INHALE-1st: Afrezza® For Youth With Newly-Diagnosed Type 1 DiabetesNCT07224321 | Mannkind Corporation | Phase 2 | Recruiting | 2027-03Estimated |
| Double-blind, Placebo-controlled Study in Adults With Major Depressive DisorderNCT07226661 | SUPN | Phase 2 | Recruiting | 2026-12-31Estimated |
| Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal CancerNCT07228832 | Summit Therapeutics | Phase 3 | Recruiting | 2028-05-31Estimated |
| A Study to Evaluate the Efficacy and Safety of OTX-TKI (Axitinib Implant) in Participants With Non-Proliferative Diabetic RetinopathyNCT07235085 | OCUL | Phase 3 | Recruiting | 2027-03Estimated |
| RGX-121-3102 Gene Therapy in Participants With MPS II (Hunter Syndrome)NCT07236606 | RGNX | Phase 3 | Active not recruiting | 2028-04-30Estimated |
| Study of Inhaled ARO-RAGE in Allergen-induced Mild AsthmaNCT07241546 | Arrowhead Pharmaceuticals | Phase 2 | Recruiting | 2027-12Estimated |
| Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-2)NCT07246590 | VRCA | Phase 3 | Active not recruiting | 2026-11Estimated |
| Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)NCT07252232 | RVMD | Phase 3 | Recruiting | 2029-05-10Estimated |
| Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous UrticariaNCT07256392 | Celldex Therapeutics | Phase 3 | Enrolling by invitation | 2028-09Estimated |
| Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic AdenocarcinomaNCT07259317 | Corcept Therapeutics | Phase 2 | Recruiting | 2027-09Estimated |
| Phase 2A/B Efficacy and Safety of Dabogratinib in Participants With Low Grade Upper Tract Urothelial CarcinomaNCT07265947 | TYRA | Phase 2 | Recruiting | 2030-10Estimated |
| A Study to Investigate Efficacy, Safety and Tolerability of Barzolvolimab Versus Placebo in Adults With Cold Induced Urticaria and Symptomatic Dermographism Inadequately Controlled by H1-antihistamines (EMBARQ - ColdU and SD)NCT07266402 | Celldex Therapeutics | Phase 3 | Recruiting | 2028-06Estimated |
Trial details
- Registry ID
- NCT07200908
- Phase
- Phase 3
Trial details
- Registry ID
- NCT07209332
- Phase
- Phase 2
Trial details
- Registry ID
- NCT07209462
- Phase
- Phase 2
Trial details
- Registry ID
- NCT07210723
- Phase
- Phase 2, Phase 3
Trial details
- Registry ID
- NCT07211633
- Phase
- Phase 3
Trial details
- Registry ID
- NCT07211776
- Phase
- Phase 3
Trial details
- Registry ID
- NCT07211958
- Phase
- Phase 3
Trial details
- Registry ID
- NCT07217015
- Phase
- Phase 2
Trial details
- Registry ID
- NCT07217860
- Phase
- Phase 3
Trial details
- Registry ID
- NCT07218146
- Phase
- Phase 3
Trial details
- Registry ID
- NCT07218783
- Phase
- Phase 3
Trial details
- Registry ID
- NCT07218796
- Phase
- Phase 3
Trial details
- Registry ID
- NCT07219407
- Phase
- Phase 2
Trial details
- Registry ID
- NCT07220252
- Phase
- Phase 2, Phase 3
Trial details
- Registry ID
- NCT07220603
- Phase
- Phase 2
Trial details
- Registry ID
- NCT07221500
- Phase
- Phase 2
Trial details
- Registry ID
- NCT07221578
- Phase
- Phase 3
Trial details
- Registry ID
- NCT07223138
- Phase
- Phase 3
Trial details
- Registry ID
- NCT07224321
- Phase
- Phase 2
Trial details
- Registry ID
- NCT07226661
- Phase
- Phase 2
Trial details
- Registry ID
- NCT07228832
- Phase
- Phase 3
Trial details
- Registry ID
- NCT07235085
- Phase
- Phase 3
Trial details
- Registry ID
- NCT07236606
- Phase
- Phase 3
Trial details
- Registry ID
- NCT07241546
- Phase
- Phase 2
Trial details
- Registry ID
- NCT07246590
- Phase
- Phase 3
Trial details
- Registry ID
- NCT07252232
- Phase
- Phase 3
Trial details
- Registry ID
- NCT07256392
- Phase
- Phase 3
Trial details
- Registry ID
- NCT07259317
- Phase
- Phase 2
Trial details
- Registry ID
- NCT07265947
- Phase
- Phase 2
Trial details
- Registry ID
- NCT07266402
- Phase
- Phase 3
Primary completion marks the end of data collection for the main study measures, not a results publication date.